Global Swollen Knee Treatment Market

Global Swollen Knee Treatment Market Size Insights Forecasts to 2035

• The Global Swollen Knee Treatment Market Size Was Estimated at USD 1.45 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.45% from 2025 to 2035
• The Worldwide Swollen Knee Treatment Market Size is Expected to Reach USD 2.60 Billion by 2035
• North America is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Decisions Advisors and Consulting, The Global Swollen Knee Treatment Market Size was worth around USD 1.45 Billion in 2024 and is predicted to Grow to around USD 2.60 Billion by 2035 with a compound annual growth rate (CAGR) of 5.45% from 2025 to 2035. The growth in the market is largely fueled by the increasing incidence of knee-related disorders, which include osteoarthritis and rheumatoid arthritis, along with growing awareness about knee health and the evolution of treatment methods. The ageing population worldwide is one of the major factors contributing to the expansion of the market for the treatment of swollen knees. The older people get, the more they are exposed to the risk of chronic conditions such as osteoarthritis. This condition is a frequent cause of swelling in the knee.

 

Market Overview

The swollen knee treatment market refers to the global healthcare segment that focuses on the diagnosis, management, and relief of knee swelling that results from arthritis, injuries, infections, or other medical conditions. It covers various products and services such as pharmaceuticals, medical devices, surgical interventions, and physiotherapy solutions. The market is driven by the growing number of sports injuries, an ageing population prone to osteoarthritis, and increasing awareness of early treatment options. The scope of treatment is being further extended by the advancements of minimally invasive procedures, biologics, and regenerative therapies. Besides this, the increasing healthcare expenditure and better access to medical facilities are some of the other factors that contribute to the market growth. In brief, the swollen knee treatment market is vital in elevating patient mobility, alleviating discomfort, and enhancing the overall quality of life through the diverse therapeutic approaches available.

 

Allay Therapeutics raised $57.5 million in Series D financing, along with a venture debt line, to advance ATX101, its ultra-sustained pain management platform designed for post-surgical pain, particularly in total knee replacement patients. The company expects Phase 2b trial results in Q4 2025.

 

ROSM being selected to lead a $1M grant-backed trial for disease-reversing osteoarthritis therapy directly connects to swollen knee treatment, since osteoarthritis is one of the primary causes of chronic knee swelling, pain, and disability. A therapy that could reverse or halt disease progression would significantly reshape the market landscape.

 

Report Coverage

This research report categorises the swollen knee treatment market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the swollen knee treatment market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the swollen knee treatment market.     

 

Driving Factors  

The swollen knee treatment market is undergoing significant changes, reflecting a range of factors such as a growing elderly population and increased awareness of joint health. Patients are becoming more aware of the implications of knee swelling, and thus, they demand effective treatment options. This market represents various therapeutic approaches that range from drug treatment and physiotherapy (conservative management techniques) to advanced surgical interventions. The rise of lifestyle-related diseases (obesity, arthritis) is the cause of knee swelling, and the demand for treatments targeted only at this problem is growing. Medical technology and pharmaceutical developments are likely to have a significant impact on the effectiveness of treatment methods in the swollen knee treatment market. New therapies, such as biologics and regenerative medicine, seem to be the future, thus providing some relief to patients suffering from chronic knee issues. Moreover, the use of telemedicine and digital health may improve patient engagement and compliance with treatment plans. The market growth to the next level requires its players to have an eye on emerging trends and to modify their strategies accordingly to be able to meet the needs of the patients.

 

A recent clinical trial found that the flavonoid supplement diosmin, derived from citrus fruits, significantly reduced swelling and pain during movement after total knee arthroplasty (TKA), without increasing short-term complications. This offers a promising new approach to managing post-surgical recovery.

 

Restraining Factors  

Despite these improvements, the medication segment continues to face challenges. Drug costs, especially for biologics and new formulations, can be very expensive. The insurance coverage and reimbursement policies are different from place to place, and this creates a challenge for patients to have access to these treatments. Besides that, the prolonged use of some medicines can cause side effects, which require continuous checking and management by healthcare professionals.

 

Market Segmentation    

The swollen knee treatment market share is classified into treatment, and end use.     

• The medication segment accounted for the largest share in 2024 and is projected to grow at a significant CAGR during the forecast period.        

Based on the treatment, the swollen knee treatment market is divided into medication, surgery, and others. Among these, the medication segment accounted for the largest share in 2024 and is projected to grow at a significant CAGR during the forecast period. Medications for a swollen knee have become the most popular and conventional treatment method mainly because they are the easiest to obtain and give quick relief. These interventions have been widely prescribed and trusted, which has contributed to their strong position in the market. They are often the first line of therapy that patients and healthcare providers turn to in case of a swollen knee.

 

• The hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the end use, the swollen knee treatment market is segmented into hospitals, clinics, and others. Among these, the hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hospitals continue to hold the largest share due to providing a wide range of cutting-edge surgical and non-surgical procedures. Their approach is characterised by advanced technology and a multidisciplinary team, which allows them to serve a diverse patient demographic and other services.

 

Regional Segment Analysis of the Swollen Knee Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the swollen knee treatment market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the Swollen Knee Treatment market over the predicted timeframe. The rise of the region is largely influenced by factors such as increasing healthcare expenditure, a rising number of elderly people, and awareness of knee health. China and India are the two countries that are heavily investing in healthcare infrastructure, which is expected to increase the demand for the market in the coming years.

 

China is the largest market in the region, followed by India and Japan. The competition in the market is changing as local and international players are both competing for market share. The main companies are focusing on strategic collaborations and product innovations to meet the different needs of patients. The presence of major pharmaceutical companies is also making it easier for more people to have access to effective treatment options throughout the region.

 

North America is expected to grow at a rapid CAGR in the swollen knee treatment market during the forecast period. The region is well equipped with state, of, the, art healthcare facilities and possesses high disposable incomes, which, coupled with a growing elderly population, continues to push up demand for effective treatment options. The market expansion is further enabled by regulatory support from agencies like the FDA, which, among other things, facilitates the approval of new therapies and technologies.

 

The US is the biggest market, where companies such as Johnson & Johnson, Pfizer, and AbbVie hold dominant positions. Canada also makes a substantial contribution, primarily by focusing on the improvement of healthcare access and the provision of treatment options for knee-related ailments, thus elevating the market dynamics.

 

The University of Miami Miller School of Medicine received FDA and Institutional Review Board (IRB) approval to launch a first-of-its-kind study in South Florida using genicular artery embolisation (GAE) for the treatment of knee osteoarthritis. This minimally invasive outpatient procedure has shown promising early results in reducing pain and improving function.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the swollen knee treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Roche Holding AG
• Sanofi S.A.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In January 2026, Biosplice Therapeutics officially submitted its New Drug Application (NDA) to the U.S. FDA for Lorecivivint (LOR), a first-in-class therapy for knee osteoarthritis. It shows both pain relief and disease-modifying potential. This marks a major milestone in osteoarthritis treatment, with FDA review now pending.

 

• In February 2024, BioSenic showcased its late-stage therapy JTA-004 for knee osteoarthritis, highlighting Phase 3 data that demonstrated safety and efficacy in patients with severe inflammatory OA. The company presented these findings at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the swollen knee treatment market based on the below-mentioned segments:

 

Global Swollen Knee Treatment Market, By Treatment

• Medication
• Surgery
• Others

 

Global Swollen Knee Treatment Market, By End Use

• Hospitals
• Clinics
• Others

 

Global Swollen Knee Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the projected size of the global swollen knee treatment market by 2035?

The market is expected to reach USD 2.60 billion by 2035, growing from USD 1.45 billion in 2024.

 

2. What is the CAGR for the swollen knee treatment market from 2025 to 2035?

The market is projected to grow at a CAGR of 5.45% during this forecast period.

 

3. Which treatment segment holds the largest market share in 2024?

The medication segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR.

 

4. Which end-use segment generated the highest revenue in 2024?

Hospitals led with the highest market revenue in 2024, driven by advanced procedures and multidisciplinary care.

 

5. Which region is anticipated to hold the largest market share?

Asia Pacific is expected to hold the largest share, fueled by rising healthcare spending and ageing populations in China and India.

 

6. Which region will grow the fastest during the forecast period?

North America is projected to grow at the fastest CAGR, supported by advanced facilities, high disposable incomes, and FDA approvals.

 

7. What are the main drivers of market growth?

Key drivers include an ageing population, rising knee disorders like osteoarthritis, increased awareness of knee health, and advancements in biologics and minimally invasive therapies.